Craneware (LON:CRW) Earns Buy Rating from Shore Capital

Craneware (LON:CRW)‘s stock had its “buy” rating reaffirmed by equities researchers at Shore Capital in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports.

Separately, Berenberg Bank reaffirmed a “buy” rating and set a GBX 2,800 ($37.25) price target on shares of Craneware in a research report on Tuesday, March 11th.

Craneware Trading Down 1.7 %

Shares of CRW stock opened at GBX 1,779.24 ($23.67) on Thursday. Craneware has a 12-month low of GBX 1,330 ($17.69) and a 12-month high of GBX 2,509.20 ($33.38). The company has a market capitalization of £764.48 million, a PE ratio of 65.74 and a beta of 0.28. The firm has a 50 day moving average price of GBX 1,720.20 and a two-hundred day moving average price of GBX 1,963.38. The company has a quick ratio of 1.00, a current ratio of 0.63 and a debt-to-equity ratio of 12.22.

Insider Buying and Selling

In other Craneware news, insider Will Whitehorn acquired 1,911 shares of Craneware stock in a transaction that occurred on Thursday, April 24th. The shares were acquired at an average cost of GBX 1,584 ($21.07) per share, with a total value of £30,270.24 ($40,269.04). 19.28% of the stock is currently owned by company insiders.

Craneware Company Profile

The Craneware Group, the market leader in automated value cycle solutions, including 340B management, collaborates with U.S. healthcare providers to plan, execute, and monitor operational and financial performance so they can continue to deliver quality care to their communities. Customers choose The Craneware Group’s Trisus data and applications platform as their key to navigating the journey to financially sustainable value-based care.